Ranbaxy's First Biosimilar Target Will Be Amgen's Neupogen
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories is set to venture into biosimilar development, targeting Amgen's neutropenia treatment Neupogen (filgrastim) as its first generic biologic, the company announced Feb. 7